Hypogonadism following long-term treatment with diethylstilbestrol.
The authors describe the abnormalities of gonadal function developing in a patient with prostate cancer who had received estrogen therapy continuously for 6 years. The pretreatment prostate biopsy showed well developed acini consistent with normal androgenization and adenocarcinoma. Twelve years later, 6 years after discontinuation of estrogen treatment, the patient presented with severe hypogonadism, gynecomastia, and primary hypothyroidism. Testicular biopsies showed ghosts of seminiferous tubules with absence of Leydig cells, and prostatic biopsies showed atrophic acini without evidence of malignancy. Despite undetectable serum testosterone levels, serum gonadotropins were inappropriately normal and responded minimally to gonadotropin-releasing hormone (GnRH) administration. Replacement therapy with levothyroxine did not correct gonadal dysfunction. Thus, prolonged estrogen therapy may result in irreversible testicular destruction and loss of the feed-back response of the hypothalamic pituitary gonadal axis.
Wortsman
J
J
Department of Medicine, Southern Illinois University, Springfield.
Hamidinia
A
A
Winters
S J
SJ
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000009:adverse effects*; D005640:Follicle Stimulating Hormone / Q000097:blood; D007987:Gonadotropin-Releasing Hormone; D006801:Humans; D007006:Hypogonadism / Q000097:blood / Q000139:chemically induced* / Q000473:pathology; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy; D013737:Testis / Q000473:pathology; D013960:Thyroid Function Tests; D013997:Time Factors
D007987:Gonadotropin-Releasing Hormone; D004054:Diethylstilbestrol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone